about us

press release

contact

Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

Breaking News

Accuredit Therapeutics and N1 Life Form a Joint Venture Named ‘Napoltec’, Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation

"We are very pleased to establish a new joint venture, Napoltec, with N1 Life, which will be featuring complementary in mutually pursuing gene therapy drug development. The N1 Life team led by Dr. Zang and Prof. Wender has accumulated years of research and development experience in novel delivery systems.

FDA Releases Federal Interagency Working Group Scientific Opinions on Testing Methods for Asbestos in Talc-Containing Cosmetic Products

Release of the white paper concludes the efforts of the IWGACP. The FDA will consider the scientific opinions presented in the white paper, including having it peer-reviewed, as part of its overall efforts to help ensure the safety of talc-containing cosmetic products.

Hekka Labs Introduces the First Decentralized Chronic Disease Data Management Ecosystem in South Asia

Hekka has cemented initial partnerships with 3 Indian healthcare solution providers, Curisin, a healthcare company with a wide network of 30 million patients and 40,000 partnered doctors which as recently agreed to provide a minimum of 1.5 million medical records in 2022.

Impact NRS LLC Creates RumenEra Inc to Develop and Commercialize High-Impact Rumen Microbiome Applications in a Joint Collaboration with National Institute for Biotechnology in the Negev and the Agricultural Research Organization

Mr. Salman continues "RumenEra is committed to the creation of a global reference standard for the rapid measurement of net feed efficiency, as well as creating products that can be applied to ruminants to optimize their efficiency while decreasing environmental burdens, naturally and healthily, for both the animals and their ecosystems."

Pharma

H.E.L Group Expands Operations in India

Expansion will focus on supporting high growth industries in India, including biotechnology, process safety, and pharmaceutical industries

Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin

“We look forward to advancing our launch plans for this important product, and we believe this withdrawal re-affirms our confidence in ultimate success,” stated Scott Tarriff, Pre and CEO Eagle Pharmaceuticals.

New Acquisitions, Mergers, Funding

Shanghai ZhenGe Biotech Raises USD 100 M

Round C proceeds will be used to strengthen R&D and build multiple 15,000L production lines, which will enable the company to deliver cost-effective and high-quality solutions for meeting growing demand from existing and new customers.

AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

"We are joined by a top syndicate of investors that understands the NTM lung disease landscape and shares our excitement that the profile of epetraborole has the potential to meet the ideal target product profile described by NTM clinicians for novel drugs needed to significantly advance the care of their patients," said Eric Easom, President and Chief Executive Officer of AN2 Therapeutics.

Clinical Trials

Frontiers in Microbiology Publishes Article Detailing Novel Microbiome-based Biomarker of Post-Antibiotic Disruptions in Gut Microbiota

The Microbiome Health Index for post-Antibiotic dysbiosis (MHI-A), published in Frontiers in Microbiology, was developed to better understand and manage the risks of antibiotic administration and help guide the development of live biotherapeutic products – a potential new class of drugs.

Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease

This Phase 2a study is intended to build on encouraging preliminary Phase 1 data that were announced in 2021.

FDA Cleared Devices & News

FDA Releases Federal Interagency Working Group Scientific Opinions on Testing Methods for Asbestos in Talc-Containing Cosmetic Products

Release of the white paper concludes the efforts of the IWGACP. The FDA will consider the scientific opinions presented in the white paper, including having it peer-reviewed, as part of its overall efforts to help ensure the safety of talc-containing cosmetic products.

Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay

"Curian Campy follows last year's successful launch of our Curian HpSA assay and is the next step in expanding our Curian test menu for gastrointestinal infections," stated Wes Lindsey, Ph.D., Vice President Global Research and Development - Diagnostics.

EXECUTIVES

Aristea Therapeutics Announces Key Leadership Appointments

James M. Mackay, Ph.D., President and CEO of Aristea, commented, "Ciara and Fabio are invaluable members of our Board and management teams, respectively. Both scientists, collectively bring decades of experience in our industry to the company.

Paul Chu, MBA, Appointed VP of Business Development at Phanes Therapeutics

Chu held senior leadership roles in both small biotech companies and large multi-national corporations and has closed deals valued at over $6 billion with a portfolio that spans across oncology, eyecare, neuroscience, and medical aesthetics.